On July 20, 2026 Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, reported the acceptance of seven abstracts covering progress across its lead programs at the 2026 European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress in Madrid, Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to have these abstracts accepted for presentation at ESMO (Free ESMO Whitepaper) this year. The presentations will cover both the progress of our pipeline and the growing body of evidence supporting differentiation of our lead programs," said Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon. "At Eikon, we are driven by a desire to bring new medicines to patients with the ultimate goal of providing meaningful benefit to people living with cancer."
ESMO Abstract Titles:
EIK1001
Title: TeLuRide-005: Phase 2 study of EIK1001 (TLR7/8 dual agonist) plus pembrolizumab and chemotherapy in patients with stage IV NSCLC: results from the squamous cohort and updated pooled results.
Title: A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (NSCLC) [TeLuRide-008]
EIK1003
Title: Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, in combination with abiraterone in patients with metastatic prostate cancer (mPC)
Title: Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, as monotherapy and in combination with paclitaxel (PTX) in advanced solid tumors
EIK1004
Title: A first-in-human Phase 1/2 study of EIK1004, a PARP1-selective CNS-penetrant
inhibitor, in patients with advanced solid tumors with HRR mutations
EIK1005
Title: Phase 1/2 Study of the Novel Werner Helicase Inhibitor EIK1005 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors, Including MSI-H or dMMR Tumors
Title: Analysis of the Safety, Tolerability, and PK of EIK1005, a Novel WRN Inhibitor
(Press release, Eikon Therapeutics, JUL 20, 2026, View Source [SID1234669335])